Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 46M | 1M | 151K |
| Gross Profit | 46M | 1M | 151K |
| Operating Income | -81M | -81M | 2M |
| EBITDA | -79M | -79M | -45M |
| Net Income | -49M | -72M | 4M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$36.17
+1.03% today
1Y Change
+243.49%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Septerna, Inc. (SEPN) is a Healthcare stock with a market cap of $1.06B and listed on NASDAQ. The stock last traded around $36.17 and up 243.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +4174.5%, EPS growth of +84.8%, a dividend yield of 0.0%. What stands out right now is revenue +4174.5%, EPS +84.8%, free cash flow +257.6% with operating margin -148.6% and ROIC -13.4%. Valuation already assumes a fairly strong business story at price/sales 23.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SEPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SEPN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SEPN Max Drawdown
-25.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SEPN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$151.0K
-86.0% YoY
FY Net Income
$4.2M
+105.8% YoY
Free Cash Flow
-$24.6M
+40.9% YoY
Revenue Growth
+4174.5%
EPS Growth
+84.8%
Gross Margin
100.0%
Net Margin
-106.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 46M | 1M | 151K |
| Gross Profit | 46M | 1M | 151K |
| Operating Income | -81M | -81M | 2M |
| EBITDA | -79M | -79M | -45M |
| Net Income | -49M | -72M | 4M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 121M | 238M | 88M | 31M |
| Total Assets | 596M | 457M | 131M | 36M |
| Total Liabilities | 214M | 37M | 169M | 80M |
| Shareholder Equity | 382M | 420M | -38M | -44M |
| Total Debt | 24M | 25M | 13M | 710K |
| Net Debt | -97M | -213M | -76M | -30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
+39.8% YoY
Capital Expenditures
1M
+55.2% YoY
Free Cash Flow
25M
+40.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-148.6%
Net Margin
-106.4%
ROE
-12.6%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.